PL2315773T3 - Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy - Google Patents

Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy

Info

Publication number
PL2315773T3
PL2315773T3 PL09781052T PL09781052T PL2315773T3 PL 2315773 T3 PL2315773 T3 PL 2315773T3 PL 09781052 T PL09781052 T PL 09781052T PL 09781052 T PL09781052 T PL 09781052T PL 2315773 T3 PL2315773 T3 PL 2315773T3
Authority
PL
Poland
Prior art keywords
tubeculosis
polynucleotides
polypeptides
latent
compositions
Prior art date
Application number
PL09781052T
Other languages
English (en)
Polish (pl)
Inventor
James Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals S.A.
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A., Glaxo Group Limited filed Critical Glaxosmithkline Biologicals S.A.
Publication of PL2315773T3 publication Critical patent/PL2315773T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
PL09781052T 2008-07-25 2009-07-24 Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy PL2315773T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
EP09781052.7A EP2315773B1 (en) 2008-07-25 2009-07-24 Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis

Publications (1)

Publication Number Publication Date
PL2315773T3 true PL2315773T3 (pl) 2017-07-31

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09781052T PL2315773T3 (pl) 2008-07-25 2009-07-24 Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy

Country Status (24)

Country Link
US (2) US20110117119A1 (enExample)
EP (1) EP2315773B1 (enExample)
JP (1) JP5873332B2 (enExample)
KR (1) KR20110044883A (enExample)
CN (1) CN102164952B (enExample)
AU (1) AU2009273130B2 (enExample)
BR (1) BRPI0916703A2 (enExample)
CA (1) CA2731499C (enExample)
CO (1) CO6341637A2 (enExample)
CY (1) CY1118200T1 (enExample)
DK (1) DK2315773T3 (enExample)
EA (1) EA024826B1 (enExample)
ES (1) ES2602430T3 (enExample)
HR (1) HRP20161458T1 (enExample)
HU (1) HUE031044T2 (enExample)
IL (1) IL210559A0 (enExample)
LT (1) LT2315773T (enExample)
MX (1) MX2011000983A (enExample)
PL (1) PL2315773T3 (enExample)
PT (1) PT2315773T (enExample)
SG (1) SG192456A1 (enExample)
SI (1) SI2315773T1 (enExample)
UA (1) UA107330C2 (enExample)
WO (1) WO2010010177A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE445638T1 (de) * 1998-11-04 2009-10-15 Isis Innovation Tuberkulose diagnose test
UA107329C2 (uk) 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv2386c, композиція, що його містить, та застосування
PT2315597T (pt) 2008-07-25 2017-11-20 Glaxosmithkline Biologicals Sa Novas composições e métodos
EP2156945A1 (en) 2008-08-13 2010-02-24 Novelis Inc. Clad automotive sheet product
CA2759583C (en) 2009-04-24 2020-06-16 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
CN102869372B (zh) 2010-01-27 2016-01-20 葛兰素史密丝克莱恩生物有限公司 经修饰的结核抗原
SG11201601692PA (en) * 2013-09-27 2016-04-28 Codexis Inc Structure based predictive modeling
CN105765592B (zh) 2013-09-27 2019-12-17 科德克希思公司 用于酶变体的自动筛选的方法、装置和系统
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
BR112019025193A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN113677664B (zh) 2019-04-12 2025-04-04 C4医药公司 Ikaros和aiolos的三环降解物
CA3142300C (en) 2019-06-05 2025-02-04 Glaxosmithkline Biologicals Sa SAPONIN PURIFICATION
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
IL138809A0 (en) * 1998-04-07 2001-10-31 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
JP5139618B2 (ja) * 2000-06-20 2013-02-06 コリクサ コーポレイション Mycobacteriumtuberculosisの融合タンパク質
US7135280B2 (en) * 2001-01-08 2006-11-14 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
EP1401866A2 (en) * 2001-02-22 2004-03-31 Institut Pasteur Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
US7678379B2 (en) * 2004-06-17 2010-03-16 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
PL2457926T3 (pl) 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
EP2163255B1 (en) * 2005-06-23 2017-08-09 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
CA2759583C (en) * 2009-04-24 2020-06-16 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
CN102869372B (zh) 2010-01-27 2016-01-20 葛兰素史密丝克莱恩生物有限公司 经修饰的结核抗原

Also Published As

Publication number Publication date
BRPI0916703A2 (pt) 2019-12-24
MX2011000983A (es) 2011-03-02
US20140178423A1 (en) 2014-06-26
UA107330C2 (uk) 2014-12-25
EP2315773B1 (en) 2016-08-24
IL210559A0 (en) 2011-03-31
CA2731499C (en) 2017-01-10
AU2009273130A1 (en) 2010-01-28
CO6341637A2 (es) 2011-11-21
JP2011528895A (ja) 2011-12-01
PT2315773T (pt) 2016-11-23
EA201100072A1 (ru) 2011-10-31
EP2315773A1 (en) 2011-05-04
CN102164952A (zh) 2011-08-24
CY1118200T1 (el) 2017-06-28
KR20110044883A (ko) 2011-05-02
JP5873332B2 (ja) 2016-03-01
DK2315773T3 (en) 2016-12-12
HUE031044T2 (en) 2017-06-28
AU2009273130B2 (en) 2014-10-16
LT2315773T (lt) 2016-11-10
SG192456A1 (en) 2013-08-30
WO2010010177A1 (en) 2010-01-28
CA2731499A1 (en) 2010-01-28
CN102164952B (zh) 2016-05-25
US9795663B2 (en) 2017-10-24
SI2315773T1 (sl) 2016-12-30
ES2602430T3 (es) 2017-02-21
HRP20161458T1 (hr) 2016-12-16
US20110117119A1 (en) 2011-05-19
EA024826B1 (ru) 2016-10-31

Similar Documents

Publication Publication Date Title
PL2315773T3 (pl) Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
PL1975226T3 (pl) Płynna kompozycja do obróbki
EP2314278A4 (en) HAIR TREATMENT COMPOSITION
IL213365A (en) Imidazopyrazine and their pharmaceutical preparations
IL207096A0 (en) Modified leptin polypeptides and their uses
PL2101731T3 (pl) Endoksyfen do zastosowania w leczeniu nowotworu
IL195152A (en) Compounds for use in treating diseases of cell culture
PL2190405T3 (pl) Kompozycje do traktowania włosów
GB0719202D0 (en) Compositions and methods for the skin and hair
PL2209458T3 (pl) Kompozycje do traktowania skóry
PL2066408T3 (pl) Kompozycja na bazie ksantoksyliny i jej zastosowanie w kosmetyce
MX303262B (es) Composicion de locion para uso personal.
ZA200905427B (en) Rasp and cover
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
GB0822486D0 (en) Compounds for use in the treatment of pain
GB0714500D0 (en) composition and treatment
GB2461611B (en) Composition and use thereof
ZA200807156B (en) Liquid treatment composition
ZA201000469B (en) Therapeutic compositions and the use thereof
GB0622040D0 (en) Skin treatment composition
GB0810409D0 (en) Composition and use thereof
GB0808877D0 (en) Composition and use thereof
GB0711036D0 (en) Composition and their use